Alpha Cognition (ACOG) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alpha Cognition (ACOG) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 17.1% versus a gain of 4.1%. InflaRx N.V. is the larger company by market cap ($225.5 million vs $196.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | IFRX |
|---|---|---|
| Share price | $9.04 | $1.53 |
| Market cap | $196.87M | $225.47M |
| 1-day change | 0.00% | -1.92% |
| YTD return | +39.08% | +51.49% |
| 1-year return | +17.10% | +4.08% |
| 5-year return | — | -38.06% |
| EPS (TTM) | $-1.32 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $2.95 |
| 52-week low | $4.50 | $0.798 |
| Distance from 52-week high | -10.85% | -48.12% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +99.12% | +401.96% |
| Average volume | 125.72K | 798.72K |
| Shares outstanding | 21.78M | 147.37M |
| Employees | 71 | 65 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed IFRX by 13.0 percentage points over the past year.
- The two companies sit in different sectors: Alpha Cognition in Healthcare and InflaRx N.V. in Health Care.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ACOG vs IFRX FAQ
Which is bigger, Alpha Cognition or InflaRx N.V.?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $225.47M compared with $196.87M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or IFRX?
ACOG returned +17.10% over the past 12 months, compared with +4.08% for IFRX (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and InflaRx N.V. in the same industry?
No. Alpha Cognition is in the Healthcare sector, while InflaRx N.V. is in Health Care.